299 related articles for article (PubMed ID: 29663815)
1. Canakinumab as monotherapy for treatment of familial Mediterranean fever - first report in Central and Eastern Europe region.
Jesenak M; Hrubiskova K; Kapustova L; Kostkova M; Banovcin P
Bratisl Lek Listy; 2018; 119(4):198-200. PubMed ID: 29663815
[TBL] [Abstract][Full Text] [Related]
2. Longterm Beneficial Effect of Canakinumab in Colchicine-resistant Familial Mediterranean Fever.
Laskari K; Boura P; Dalekos GN; Garyfallos A; Karokis D; Pikazis D; Settas L; Skarantavos G; Tsitsami E; Sfikakis PP
J Rheumatol; 2017 Jan; 44(1):102-109. PubMed ID: 28042127
[TBL] [Abstract][Full Text] [Related]
3. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.
Kurt T; Aydın F; Nilüfer Tekgöz P; Sezer M; Uncu N; Çelikel Acar B
Int J Rheum Dis; 2020 Jul; 23(7):977-981. PubMed ID: 32558310
[TBL] [Abstract][Full Text] [Related]
4. Approach to the patients with inadequate response to colchicine in familial Mediterranean fever.
Gül A
Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):296-303. PubMed ID: 27886801
[TBL] [Abstract][Full Text] [Related]
5. The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review.
Hentgen V; Vinit C; Fayand A; Georgin-Lavialle S
Front Immunol; 2020; 11():971. PubMed ID: 32670263
[No Abstract] [Full Text] [Related]
6. Canakinumab for the treatment of familial Mediterranean fever.
Ozdogan H; Ugurlu S
Expert Rev Clin Immunol; 2017 May; 13(5):393-404. PubMed ID: 28362189
[TBL] [Abstract][Full Text] [Related]
7. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents.
Eroglu FK; Beşbaş N; Topaloglu R; Ozen S
Rheumatol Int; 2015 Oct; 35(10):1733-7. PubMed ID: 26001859
[TBL] [Abstract][Full Text] [Related]
8. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
De Benedetti F; Gattorno M; Anton J; Ben-Chetrit E; Frenkel J; Hoffman HM; Koné-Paut I; Lachmann HJ; Ozen S; Simon A; Zeft A; Calvo Penades I; Moutschen M; Quartier P; Kasapcopur O; Shcherbina A; Hofer M; Hashkes PJ; Van der Hilst J; Hara R; Bujan-Rivas S; Constantin T; Gul A; Livneh A; Brogan P; Cattalini M; Obici L; Lheritier K; Speziale A; Junge G
N Engl J Med; 2018 May; 378(20):1908-1919. PubMed ID: 29768139
[TBL] [Abstract][Full Text] [Related]
9. Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever.
Kucuksahin O; Yildizgoren MT; Ilgen U; Ates A; Kinikli G; Turgay M; Erten S
Mod Rheumatol; 2017 Mar; 27(2):350-355. PubMed ID: 27328763
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Canakinumab in Colchicine- and Anakinra-Resistant or -Intolerant Adult Familial Mediterranean Fever Patients: A Single-Center Real-Life Study.
Babaoglu H; Varan O; Kucuk H; Atas N; Satis H; Salman R; Ozturk MA; Goker B; Tufan A; Haznedaroglu S
J Clin Rheumatol; 2020 Jan; 26(1):7-13. PubMed ID: 30048391
[TBL] [Abstract][Full Text] [Related]
11. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever.
Şahin A; Derin ME; Albayrak F; Karakaş B; Karagöz Y
Adv Rheumatol; 2020 Jan; 60(1):12. PubMed ID: 32000860
[TBL] [Abstract][Full Text] [Related]
12. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis.
Özçakar ZB; Özdel S; Yılmaz S; Kurt-Şükür ED; Ekim M; Yalçınkaya F
Clin Rheumatol; 2016 Feb; 35(2):441-6. PubMed ID: 25213327
[TBL] [Abstract][Full Text] [Related]
13. The clinical role of anakinra in the armamentarium against familial Mediterranean fever.
Parlar K; Ates MB; Egeli BH; Ugurlu S
Expert Rev Clin Immunol; 2024 May; 20(5):441-453. PubMed ID: 38133629
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature.
Meinzer U; Quartier P; Alexandra JF; Hentgen V; Retornaz F; Koné-Paut I
Semin Arthritis Rheum; 2011 Oct; 41(2):265-71. PubMed ID: 21277619
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis.
Varan Ö; Kucuk H; Babaoglu H; Guven SC; Ozturk MA; Haznedaroglu S; Goker B; Tufan A
Mod Rheumatol; 2019 Mar; 29(2):363-366. PubMed ID: 29578360
[TBL] [Abstract][Full Text] [Related]
16. Familial Mediterranean fever, review of the literature.
Alghamdi M
Clin Rheumatol; 2017 Aug; 36(8):1707-1713. PubMed ID: 28624931
[TBL] [Abstract][Full Text] [Related]
17. Down-regulated Th17 cells in a patient with familial Mediterranean fever associated with amyloid A amyloidosis in the treatment of canakinumab.
Goto T; Miyazaki Y; Nakayamada S; Shiraishi N; Yoshinaga T; Tanaka Y; Nakamura T
Mod Rheumatol Case Rep; 2023 Jan; 7(1):237-242. PubMed ID: 35349715
[TBL] [Abstract][Full Text] [Related]
18. Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment.
Karabulut Y; Gezer HH; Duruöz MT
Rheumatol Int; 2022 Jan; 42(1):81-86. PubMed ID: 34550430
[TBL] [Abstract][Full Text] [Related]
19. Canakinumab treatment in four children with colchicine resistant familial mediterranean fever.
Ozkan S; Atas B
J Pak Med Assoc; 2017 Jun; 67(6):945-947. PubMed ID: 28585601
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Canakinumab Treatment in Recipients of Kidney Transplant With Familial Mediterranean Fever: A Case Series.
Sendogan DO; Saritas H; Kumru G; Eyupoglu S; Sadioglu RE; Tuzuner A; Sengul S; Keven K
Transplant Proc; 2019 Sep; 51(7):2292-2294. PubMed ID: 31400972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
